When you understand the science and logic involved in MIT, and start perceiving potentized drugs in terms of diverse types of ‘molecular imprints’ as the ‘active principles’ they contain, you will realize that all controversies over ‘single/multiple’ drug issue leveled against MIT become totally irrelevant.
According to MIT view, ‘similimum’ essentially means a drug substance that can provide the specific molecular imprints required to remove the particular molecular errors that caused the particular disease condition in the particular patient. Whatever be the ‘method’ by which the drug is selected, similimum is a similimum if it serves the purpose of curing the patient when administered in potentized form.
Since ‘multiple’ molecular errors exist in any patient in a particular point of time, expressed through ‘multiple’ groups of symptoms, he will inevitably need ‘multiple’ molecular imprints to remove them. If potentized form of a ‘single’ medicinal substance can provide all those ‘multiple’ molecular imprints, that ‘single’ drug substance will be enough. If we could not find a ‘single’ drug substance that contain ‘all’ the ‘multiple’ molecular imprints required by the patient as indicated by the ‘symptom groups’, we will have to include ‘multiple’ drug substances in our prescription. It is the constituent molecular imprints contained in our particular prescription that matter.
Important point is, we have to ensure that our prescription supplies all the diverse types of molecular imprints required for deactivating all the diverse types of pathogenic molecules existing in the patient, as indicated by the diverse groups of subjective and objective symptoms expressed by him. If we could find a single drug preparation that could supply all the molecular imprints required by the patient I am dealing with, we can use that single drug preparation only. If we do not find such a single drug, we have to include as many number of drug preparations as required, in order to provide all the molecular imprints needed to remove all the molecular errors in the patient.
‘Single/multiple’ drug controversy never bothers one who understands this scientific approach proposed by MIT, as we start thinking in terms of molecular imprints- not in terms of drug names. Actually, a drug becomes ‘single’, if it contains ‘single’ type of molecular imprints only. IF a drug contains more than one type of molecular imprints, it is a compound drug, even if it is known by a ‘single’ drug name, prepared from a ‘single’ source material, kept in a ‘single’ bottle, consumed as a ‘single’ unit for ‘drug proving’, or considered by ‘masters’ as ‘single’ drug.
When we consume a complex drug substance in crude form, it is absorbed into the blood as various individual chemical molecules contained in it. It is these individual chemical molecules that interact with various biological molecules. Different molecules act up on different biological targets according to the molecular affinities of their functional groups. Biological molecules are inhibited, resulting in errors in the biochemical pathways mediated by those biological molecules. Such molecular level errors in biological processes cascades into a series of molecular errors, which are expressed through various groups of subjective and objective symptoms.
It is obvious that what we consider as the symptoms of that drug substance are actually the sum total of different symptom groups, representing entirely different molecular errors produced in entirely different biological molecules, by the actions of entirely different chemical molecules contained in the crude drug.
We have to remember, there is no such a thing called nux vomica molecule or pulsatilla molecule- only individual chemical molecules contained in nux vomica or pulsatilla tinctures. Each constituent molecule has its own specific chemical structure and properties. They act on different biological targets by their chemical properties.
Each individual chemical molecule contained in a complex crude drug substance acts as an individual drug. That means, nux vomica or pulsatilla are not single drugs as we are taught, but compound drugs. Classical homeopaths may find it difficult to accept this fact, as it contradicts with their beliefs as well as the lessons they are taught. But it is the scientific fact.
From scientific point of view of pharmaceutical chemistry, a drug is a biologically active unit contained in a substance used as therapeutic agent. It is the structure and properties of that chemical molecule that decides its medicinal properties and therapeutic actions. if such as substance contains only one type of biologically active unit, it is a single drug. If it contains different types of biologically active units, it is a compound drug. It is obvious that most of the drugs we use in homeopathy – especially drugs of biological origin and complex minerals- contain diverse types of biologically active units, and hence they cannot be considered single drugs.
Molecular imprinting happens as individual molecules, and as such, potentized drugs prepared from a single drug substance will contain diverse types of molecular imprints representing the diverse types of individual constituent molecules contained in the substance. Those molecular imprints also act as individual units when applied in the organism. Hence, potentized drugs prepared by using a complex, seemingly single drug substance is actually a compound drug, containing diverse types of biologically active units, or ‘molecular imprints’.
‘Combinations’ of potentized drugs:
A serious objection against MIT from the side of classical homeopaths is regarding ‘mixing’ or ‘combinations’ of potentized drugs. On the other hand, MIT says that it is permissible for to use combinations of ‘molecular imprinted’ forms (potencies above Avogadro limit- 12c and onwards) of two or more homeopathic drugs selected on the basis of analysis of totality of symptoms, miasmatic study and biochemical evaluation of the individual patient.
MIT view is that it is effective as palliatives to use ‘disease-specific’ combinations of ‘molecular imprinted’ forms (potencies above Avogadro limit- 12c and onwards) of two or more homeopathic drugs selected on the basis of common symptoms and biochemical evaluations of specific diseases. But such ‘disease-specific’ combinations will not offer ‘total cure’ for patients, without incorporating drugs selected on the basis of symptoms also. This approach also is very close to the method of ‘banerji protocols’ that makes ‘specific’ prescriptions based on ‘disease diagnosis’ as well as symptomatology..
I am talking on the basis of my concepts of ‘molecular imprinting’ involved in potentization. I perceive all crude drugs as combinations of diverse types of constituent drug molecules. I perceive even the so called potentized ‘single’ drug as combinations of diverse types of individual drug molecules contained in the drug substance used for potentization.
My stand on this issue is based on my understanding of diseases as multitudes of pathological derangement in the organism, caused by diverse of types of molecular inhibitions caused by different types of pathogenic agents, and therapeutics involves the removal of those inhibitions using appropriate molecular imprints.
I am talking on the basis of my understanding of ‘similia similibus curentur’ as: “pathological molecular inhibitions caused by specific pathogenic molecules and expressed through a certain group of subjective and objective symptoms, could be removed by applying ‘molecular imprints’ of drug molecules that could create similar molecular inhibitions and symptoms in a healthy organism when applied in crude form.
That makes the difference between my views and classical homeopathy. I know, homeopaths trained and experienced in classical homeopathy cannot agree with my views on this topic.